IS7189A - Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra - Google Patents

Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra

Info

Publication number: IS7189A
Authority: IS; Iceland
Prior art keywords: somatostatin; diagnosis; treatment; bombesin analogues; bombesin
Prior art date: 2001-09-21

Application number

IS7189A

Other languages

English (en)

Inventor

H. Coy David

A. Fuselier Joseph

A. Murphy William

Sun Lichun

Original Assignee

The Administrators Of The Tulane Educational Fund

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-21

Filing date

2004-03-19

Publication date

2004-03-19

2004-03-19 Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund

2004-03-19 Publication of IS7189A publication Critical patent/IS7189A/is

Links

102000005157 Somatostatin Human genes 0.000 title 1
108010056088 Somatostatin Proteins 0.000 title 1
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 title 1
238000003745 diagnosis Methods 0.000 title 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
229960000553 somatostatin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Percussion Or Vibration Massage (AREA)

IS7189A 2001-09-21 2004-03-19 Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra IS7189A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32385101P	2001-09-21	2001-09-21
PCT/US2002/030143 WO2003028527A2 (en)	2001-09-21	2002-09-20	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Publications (1)

Publication Number	Publication Date
IS7189A true IS7189A (is)	2004-03-19

Family

ID=23260992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7189A IS7189A (is)	2001-09-21	2004-03-19	Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra

Country Status (16)

Country	Link
US (1)	US7326685B2 (is)
EP (1)	EP1435826A4 (is)
JP (1)	JP4799820B2 (is)
KR (1)	KR20040047846A (is)
CN (1)	CN1589151A (is)
AU (1)	AU2002341792B2 (is)
BR (1)	BR0212897A (is)
CA (1)	CA2461099A1 (is)
IL (2)	IL160993A0 (is)
IS (1)	IS7189A (is)
MX (1)	MXPA04002621A (is)
NO (1)	NO20041186L (is)
NZ (1)	NZ532204A (is)
PL (1)	PL369336A1 (is)
WO (1)	WO2003028527A2 (is)
ZA (1)	ZA200402698B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6721705B2 (en) *	2000-02-04	2004-04-13	Webley Systems, Inc.	Robust voice browser system and voice activated device controller
US7771727B2 (en) *	2002-03-01	2010-08-10	The Administrators Of The Tulane Educational Fund	Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US8060626B2 (en) *	2008-09-22	2011-11-15	Sony Computer Entertainment America Llc.	Method for host selection based on discovered NAT type
US7977049B2 (en) *	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US8709998B2 (en) *	2003-04-22	2014-04-29	Ipsen Pharma S.A.S.	Peptide vectors
US20050096256A1 (en) *	2003-07-01	2005-05-05	President And Fellows Of Harvard College	Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) *	2003-07-01	2006-02-02	President And Fellows Of Harvard College	Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP1708689A2 (en)	2003-12-29	2006-10-11	The President and Fellows of Harvard College	Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US20050255045A1 (en) *	2004-05-13	2005-11-17	Woltering Eugene A	Surgical marking composition and method
WO2005110485A1 (en) *	2004-05-14	2005-11-24	Interface Biologics Inc.	Polymeric coupling agents and pharmaceutically-active polymers made therefrom
CA2467321A1 (en) *	2004-05-14	2005-11-14	Paul J. Santerre	Polymeric coupling agents and pharmaceutically-active polymers made therefrom
US20060084085A1 (en) *	2004-06-16	2006-04-20	Sinclair David A	Methods and compositions for modulating Bax-mediated apoptosis
WO2006004722A2 (en) *	2004-06-30	2006-01-12	Biomol Research Laboratories, Inc.	Compositions and methods for selectively activating human sirtuins
WO2006138418A2 (en) *	2005-06-14	2006-12-28	President And Fellows Of Harvard College	Improvement of cognitive performance with sirtuin activators
CN102772358A (zh) *	2005-06-16	2012-11-14	美瑞德生物工程公司	药物组合物及其用途
US8735177B2 (en)	2006-02-23	2014-05-27	Adeka Corporation	Diagnostic marker
DE102006035083A1 (de) *	2006-07-28	2008-01-31	medac Gesellschaft für klinische Spezialgeräte mbH	Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
ES2410207T3 (es)	2006-10-16	2013-07-01	The Salk Institute For Biological Studies	Antagonistas de la somatostatina selectivos para receptor(SSTR2)
US8691761B2 (en)	2006-10-16	2014-04-08	Jean E. F. Rivier	Somatostatin receptor 2 antagonists
WO2008051421A2 (en) *	2006-10-20	2008-05-02	Ipsen Pharma S.A.S.	Peptide-cytotoxic conjugates
EP2144887A4 (en) *	2007-04-10	2012-10-03	Myrexis Inc	PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
CA2720989A1 (en) *	2007-04-10	2008-10-16	Myrexis, Inc.	Methods for treating cancer
KR20100016385A (ko) *	2007-04-10	2010-02-12	미리어드 파마슈티칼스, 인코포레이티드	뇌종양 치료방법
NZ580867A (en) *	2007-04-10	2011-02-25	Myriad Pharmaceuticals Inc	Method of treating melanoma
WO2008124828A1 (en) *	2007-04-10	2008-10-16	Myriad Genetics, Inc.	Methods for treating vascular disruption disorders
WO2012112792A2 (en)	2011-02-17	2012-08-23	The Administrators Of The Tulane Educational Fund	Multicomponent compositions and their uses
US20160017058A1 (en) *	2013-03-14	2016-01-21	The California Institute For Biomedical Research	Bispecific antibodies and uses thereof
US12252534B2 (en)	2016-02-04	2025-03-18	The Scripps Research Institute	Humanized anti-CD3 antibodies, conjugates and uses thereof
AU2017217271C1 (en)	2016-02-09	2021-08-05	Cdrd Ventures Inc.	Somatostatin receptor antagonist compounds and methods of using the same
EP3433259B1 (en)	2016-03-24	2021-06-30	The Administrators of The Tulane Educational Fund	Conjugates of tacrolimus, their compositions, and their uses
EP3717019A4 (en) *	2017-11-28	2021-09-22	Board of Regents of the University of Nebraska	RADIOPHARMACEUTICALS AND METHOD OF USE THEREOF
EP3740494A4 (en)	2018-02-02	2021-11-03	Ripple Therapeutics Corporation	GLASS FORMULATIONS WITH STEROID DIMERS AND USES THEREOF
US20210000988A1 (en) *	2018-03-15	2021-01-07	Osaka University	Pharmaceutical composition containing 211at-labeled amino acid derivative, and method for producing said pharmaceutical composition
WO2020154815A1 (en)	2019-02-01	2020-08-06	Ripple Therapeutics Corporation	Crystalline forms of dexamethasone dimers and uses thereof
US12509469B2 (en)	2019-08-07	2025-12-30	Ripple Therapeutics Corporation	Compositions and methods for the treatment of pain and dependence disorders
CA3176134A1 (en)	2020-05-01	2021-11-04	Ripple Therapeutics Corporation	Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4904642A (en)	1985-09-12	1990-02-27	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
US4812590A (en)	1987-06-25	1989-03-14	Merck & Co., Inc.	Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US5073541A (en) *	1987-11-18	1991-12-17	Administrators Of The Tulane Educational Fund	Treatment of small cell lung cancer with somatostatin analogs
US5753627A (en)	1988-12-05	1998-05-19	Novartis Ag	Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5633263A (en)	1989-04-26	1997-05-27	The Administrators Of The Tulane Educational Fund	Linear somatostatin analogs
ATE120374T1 (de)	1989-07-20	1995-04-15	Sandoz Ag	Markierte polypeptidderivate.
EP0450480B1 (en) *	1990-04-06	1995-06-21	The Administrators of The Tulane Educational Fund	Somatostatin Analogues
US5443815A (en)	1991-11-27	1995-08-22	Diatech, Inc.	Technetium-99m labeled peptides for imaging
US5411943A (en)	1992-02-25	1995-05-02	Biomeasure, Inc.	Hepatoma treatment with somatostatin analogs
US5620675A (en) *	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
US5597894A (en) *	1995-06-05	1997-01-28	The Louisiana State University Medical Center Foundation	Multi-tyrosinated somatostatin analogs
US6051554A (en)	1995-06-07	2000-04-18	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
US5770687A (en)	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
US5708135A (en)	1995-09-29	1998-01-13	Biomeasure Incorporated	Cyclic peptide analogs of somatostatin
US5750499A (en)	1995-10-18	1998-05-12	The Salk Institute For Biological Studies	Receptor-selective somatostatin analogs
US5843903A (en) *	1995-11-27	1998-12-01	The Administrators Of The Tulane Educational Fund	Targeted cytotoxic anthracycline analogs
US6156725A (en)	1996-08-16	2000-12-05	National Institute Of Immunology	Drug for the treatment of cancer
WO1998047524A1 (en)	1997-04-22	1998-10-29	Curators Of The University Of Missouri	Gastrin receptor-avid peptide conjugates
AU4267700A (en) *	2000-01-13	2001-07-19	Academia Sinica	Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
AU2002305845B2 (en) *	2001-06-08	2006-03-30	Ipsen Pharma S.A.S.	Somatostatin-dopamine chimeric analogs

2002
- 2002-09-20 BR BR0212897-7A patent/BR0212897A/pt not_active IP Right Cessation
- 2002-09-20 AU AU2002341792A patent/AU2002341792B2/en not_active Ceased
- 2002-09-20 CN CNA028230817A patent/CN1589151A/zh active Pending
- 2002-09-20 KR KR10-2004-7004173A patent/KR20040047846A/ko not_active Ceased
- 2002-09-20 IL IL16099302A patent/IL160993A0/xx unknown
- 2002-09-20 EP EP02775944A patent/EP1435826A4/en not_active Withdrawn
- 2002-09-20 MX MXPA04002621A patent/MXPA04002621A/es active IP Right Grant
- 2002-09-20 PL PL02369336A patent/PL369336A1/xx not_active Application Discontinuation
- 2002-09-20 JP JP2003531872A patent/JP4799820B2/ja not_active Expired - Fee Related
- 2002-09-20 WO PCT/US2002/030143 patent/WO2003028527A2/en not_active Ceased
- 2002-09-20 US US10/490,326 patent/US7326685B2/en not_active Expired - Fee Related
- 2002-09-20 NZ NZ532204A patent/NZ532204A/en not_active IP Right Cessation
- 2002-09-20 CA CA002461099A patent/CA2461099A1/en not_active Abandoned
2004
- 2004-03-19 IS IS7189A patent/IS7189A/is unknown
- 2004-03-21 IL IL160993A patent/IL160993A/en not_active IP Right Cessation
- 2004-03-22 NO NO20041186A patent/NO20041186L/no not_active Application Discontinuation
- 2004-04-06 ZA ZA200402698A patent/ZA200402698B/en unknown

Also Published As

Publication number	Publication date
KR20040047846A (ko)	2004-06-05
JP4799820B2 (ja)	2011-10-26
CA2461099A1 (en)	2003-04-10
IL160993A (en)	2011-04-28
AU2002341792B2 (en)	2007-09-06
US20050070470A1 (en)	2005-03-31
JP2005505580A (ja)	2005-02-24
US7326685B2 (en)	2008-02-05
WO2003028527A3 (en)	2003-10-30
EP1435826A2 (en)	2004-07-14
NO20041186L (no)	2004-05-05
WO2003028527A8 (en)	2004-04-15
NZ532204A (en)	2006-04-28
WO2003028527A2 (en)	2003-04-10
CN1589151A (zh)	2005-03-02
BR0212897A (pt)	2004-08-24
ZA200402698B (en)	2005-04-25
PL369336A1 (en)	2005-04-18
EP1435826A4 (en)	2009-07-15
MXPA04002621A (es)	2004-07-08
IL160993A0 (en)	2004-08-31

Publication	Publication Date	Title
NO20041186L (no)	2004-05-05	Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav
DK1404809T3 (da)	2014-03-17	Forbedrede hudsubstitutter og anvendelser deraf
DE60237823D1 (de)	2010-11-11	Medizinisches behandlungsinstrument
NO20030832L (no)	2003-04-22	Kondenserte sykliske forbindelser og medisinsk anvendelse derav
EP1417988A4 (en)	2008-05-07	RESPIRATORY EQUIPMENT
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20044195L (no)	2004-10-01	Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20035156L (no)	2004-01-20	Fremgangsmåter for brønnbehandling
NO20034159D0 (no)	2003-09-18	Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
NO20055568D0 (no)	2005-11-24	Substituerte 1,4-diazepiner og anvendelser derav
FR2846545B1 (fr)	2005-09-09	Implant d'osteosynthese intramedullaire
NO20051503D0 (no)	2005-03-21	Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
IL157328A0 (en)	2004-02-19	Treatment involving dkk-1 or antagonists thereof
DE60205718D1 (de)	2005-09-29	Flexibler wellschlauch und anschlussverfahren
DE60223576D1 (de)	2007-12-27	Hautbehandlungszusammensetzung
DK1355668T3 (da)	2008-05-05	Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
IS7275A (is)	2004-05-21	Samsetning fyrir hollegg og notkun á henni
DE60220220D1 (de)	2007-07-05	Blutbehandlungssystem
DE60222664D1 (de)	2007-11-08	Hautbehandlungsmittel
SG106109A1 (en)	2004-09-30	Tomography or curved surfaces
DE60114244D1 (de)	2005-11-24	Osteosynthesevorrichtung
DE50209299D1 (de)	2007-03-08	Chirurgisches schälmesser
DE60228736D1 (de)	2008-10-16	Menschliches bmcc1-gen
AU2003298547A8 (en)	2004-05-04	2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
GB0303016D0 (en)	2003-03-12	Science technology and invention processor version 1.0.